Absci Corporation (NASDAQ:ABSI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Seven analysts have given Absci Corporation (NASDAQ:ABSI) a consensus rating of "Moderate Buy," with an average 12-month price target of $7.66. The company, which specializes in AI-driven protein-based drug discovery, recently saw its CEO sell shares, while major institutional investors like ARK, Vanguard, and State Street increased their stakes. Absci's stock opened at $2.65, has a market cap of $398.48 million, and a 52-week range of $2.01–$5.41.
Absci Advances Lead AI-Designed Candidate for IBD into the Clinic
Absci has advanced its lead AI-designed candidate, ABS-101, for inflammatory bowel disease (IBD) into clinical trials. The company reported dosing the first healthy volunteers in a Phase I trial targeting tumor necrosis factor-like cytokine 1A (TL1A) and expects interim data in the second half of this year. Absci claims its AI platform significantly accelerated drug development, bringing ABS-101 to the clinic in just over 24 months for approximately $15 million, dramatically reducing both time and cost compared to traditional methods.
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company utilizing generative AI for therapeutic development, announced its participation in four upcoming investor conferences in March 2026. The company will engage in fireside chats and host one-on-one meetings with investors at events including the TD Cowen 46th Annual Health Care Conference and Leerink Partners 2026 Global Healthcare Conference. Webcasts of the fireside chats will be available on Absci's investor relations website.
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (Nasdaq: ABSI) announced its participation in several upcoming investor conferences in March 2026, including fireside chats and one-on-one meetings at the TD Cowen 46th Annual Health Care Conference, Leerink Partners 2026 Global Healthcare Conference, Jefferies 2026 Biotech on the Beach Summit, and KeyBanc Capital Markets Healthcare Forum. The clinical-stage biopharmaceutical company will discuss its Integrated Drug Creation™ platform, which combines AI and synthetic biology to advance breakthrough therapeutics, including its lead candidate ABS-201™ for hair regrowth and endometriosis.
AI-driven drug developer Absci lines up four March investor events
Absci (Nasdaq: ABSI), an AI-driven biopharmaceutical company, announced its participation in four investor conferences in March 2026. The company will host fireside chats and one-on-one meetings at events including TD Cowen, Leerink Partners, Jefferies Biotech on the Beach, and KeyBanc Healthcare Forum. Webcasts for most fireside chats will be available on Absci's investor relations website.
ABSI stock up on initiating dosing in androgenetic alopecia study
Abeona Therapeutics (ABSI) stock rose after the company announced the initiation of a phase 1/2 clinical study for its investigational gene therapy, ABO-503, for the treatment of androgenetic alopecia. The study aims to evaluate the safety and efficacy of the gene therapy, which targets a gene associated with hair loss. This marks a significant step for Abeona's dermatology pipeline.
Insiders Who Purchased US$582.6k Of Absci Stock May Not Have Expected 17% Tumble
Insiders at Absci Corporation purchased US$582.6k worth of stock at an average price of US$2.98, but have seen a 17% decline, reducing their investment to US$495.3k. Despite this, the article notes that overall, insiders were net buyers over the last year, suggesting confidence in the company, though recent insider selling slightly outweighed buying. The current insider ownership stands at 6.2%, indicating some alignment between management and shareholders.
In the Wake of Absci Corporation's (NASDAQ:ABSI) Latest US$75m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions
Institutional investors hold a significant majority stake (65%) in Absci Corporation (NASDAQ:ABSI), making them highly influential in its share price. Following a recent US$75 million market cap drop and a 17% share price fall, these institutions may face pressure to sell, potentially impacting individual investors. Insiders own 5.8% of the shares, while the general public holds 24%, with the leading institutional holders being FMR LLC (15%), followed by others who collectively own more than half the company.
Insiders Who Purchased US$582.6k Of Absci Stock May Not Have Expected 17% Tumble
Insiders at Absci Corporation (NASDAQ:ABSI) purchased US$582.6k worth of stock over the last year at an average price of US$2.98. A recent 17% stock tumble means their investment is now worth US$495.3k. Despite the recent dip, insider buying activity, particularly a significant purchase by an Independent Director, suggests continued confidence in the company's future, although there was slightly more selling than buying recently.
Insiders Who Purchased US$582.6k Of Absci Stock May Not Have Expected 17% Tumble
Insiders at Absci Corporation purchased US$582.6k worth of stock over the last year at an average price of US$2.98. Despite this investment, the stock has since tumbled by 17%, reducing their initial investment to US$495.3k. While insiders were net buyers, the recent decline might be a disappointment for them.
Insider Selling: Absci (NASDAQ:ABSI) CEO Sells 26,761 Shares of Stock
Absci's CEO, Sean McClain, sold 26,761 shares of Absci (NASDAQ:ABSI) stock on February 2nd for approximately $80,015, reducing his stake by 0.32%. This sale follows weak quarterly results where the company missed EPS and revenue estimates. Despite mixed analyst coverage, the consensus rating for Absci is "Moderate Buy" with an average price target of $7.66.
Absci Corporation (ABSI) Stock Analysis: Exploring the 173.66% Potential Upside in Biotech AI Innovations
Absci Corporation (ABSI) is leveraging AI in drug discovery to revolutionize antibody therapeutics. Despite current financial challenges typical of early-stage biotech, the company shows significant potential with strong analyst ratings, an average target price suggesting a 173.66% upside, and strategic collaborations. Absci presents an intriguing, high-risk opportunity for investors in the burgeoning biotech and AI intersection.
Absci Corporation (NASDAQ:ABSI) Given Average Recommendation of "Moderate Buy" by Brokerages
Absci Corporation (NASDAQ:ABSI) has received an average "Moderate Buy" rating from seven brokerage firms, with an average 12-month price target of $7.66. This comes despite the company missing recent quarterly EPS and revenue estimates, with shares trading around $2.89. Absci's Integrated Drug Creation® platform, leveraging machine learning and synthetic biology, continues to attract institutional investors, who hold approximately 52% of the stock.
Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures
Absci Corporation (NASDAQ:ABSI) has experienced a 12% stock pullback, contributing to a year-long loss, which significantly impacts institutional owners who hold 64% of the company's shares. This high institutional ownership means their trading actions can greatly affect the stock price, and continued decline might pressure them to sell, potentially harming individual investors. Insiders also hold 5.8% of the shares, showing some alignment of interests, while the general public owns 24%.
H.B. Fuller, Caledonia Mining And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were down on Thursday morning, with several notable companies experiencing declines in pre-market trading. H.B. Fuller Company (NYSE: FUL) shares fell after its fourth-quarter sales missed analyst estimates, despite beating on earnings. Other companies like Caledonia Mining Corporation PLC (NYSE: CMCL), TryHard Holdings Ltd (NASDAQ: THH), and Trip.com Group Ltd (NASDAQ: TCOM) also saw their stock prices drop due to various company-specific news and market factors.
Absci Unveils Origin-1 AI Model, Teases 2025 Hair-Loss Data and Q4 Endometriosis Trial Launch
Absci announced the release of its Origin-1 AI model for de novo antibody design, aimed at "zero prior epitopes" and hard-to-drug targets, utilizing a rapid "wet lab in the loop" validation. The company also provided updates on its ABS-201 program, a prolactin receptor antibody, highlighting dramatic preclinical hair regrowth data and plans for a Phase I/II-A trial. Additionally, Absci teased a Q4 trial launch for endometriosis with a Phase II readout expected a year later, emphasizing its platform's speed and cost-effectiveness compared to traditional drug development.
Absci Unveils Origin-1 AI Model, Teases 2025 Hair-Loss Data and Q4 Endometriosis Trial Launch
Absci showcased its new Origin-1 AI model for de novo antibody design, specifically targeting "zero prior epitopes" for hard-to-drug targets, during the 44th JPMorgan Healthcare Conference. The company also provided updates on its clinical programs, including promising preclinical hair regrowth data for its ABS-201 prolactin receptor antibody in androgenic alopecia, with clinical trial readouts expected in 2025, and plans to initiate an endometriosis trial in Q4 with Phase II data a year later. Absci emphasized its platform's speed and cost-effectiveness, claiming the ability to reach the clinic in approximately two years for about $15 million.
Absci Corp Presents Business Update at J.P. Morgan Healthcare Conference
Absci Corp presented a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company highlighted its generative AI platform for drug creation and discussed promising preclinical results for ABS-201, which targets androgenetic alopecia. Phase 1/2a trials for ABS-201 in both AGA and endometriosis are currently underway, with the drug aiming to redefine treatment categories due to its novel mechanisms and significant market potential.
Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials
Morgan Stanley downgraded Absci Corporation (ABSI) to Equalweight and lowered its price target, citing higher risk and limited near-term visibility after its Q3 update. The firm removed the underperforming ABS-101 program from its model and replaced it with ABS-201, a speculative androgenetic alopecia treatment, assigning a 25% probability of success. Analysts highlighted elevated execution risk due to the program's early stage and Absci's less established competitive position in dermatology.
Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials
Morgan Stanley downgraded Absci Corporation (ABSI) to Equalweight and cut its price target to $4.32 from $5.80 due to increased risk and limited near-term visibility. This follows interim Phase 1 data for ABS-101 falling short of expectations, leading Absci to shift focus to ABS-201, a program for androgenetic alopecia. Analysts caution about execution risk given the early stage of ABS-201 and Absci's less established competitive position in dermatology.
Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials
Morgan Stanley downgraded Absci Corporation (NASDAQ:ABSI) to Equalweight and cut its price target to $4.32 from $5.80 due to higher risk and limited near-term visibility after its third-quarter update. The firm removed the underperforming ABS-101 program from its financial model and replaced it with ABS-201, a new program targeting androgenetic alopecia, which has shown promising preclinical data. Analysts noted elevated execution risk for ABS-201 given its early stage and the company's independent development plan in less established dermatology markets.
10 Best Penny Stocks to Buy for 2026
This article identifies Absci Corporation (NASDAQ: ABSI) as one of the best penny stocks to buy for 2026, noting its 122.67% upside potential and current share price of $3.40. Despite a recent downgrade by Morgan Stanley due to underperforming Phase 1 data for ABS-101 and a shift in development strategy, Absci is exploring alternative indications and partnerships, including a new program targeting androgenetic alopecia with preclinical data showing promise. The company leverages its AI platform to develop protein-based therapeutics, with interim Phase 1/2a data for ABS-201 expected in mid-2026.
JonesTrading Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $9
JonesTrading analyst Debanjana Chatterjee has reiterated a "Buy" rating on Absci Corp (ABSI.US), maintaining a target price of $9. According to TipRanks data, the analyst has a strong track record with a 70.9% success rate and an average return of 32.5% over the past year. The information is provided for informational purposes and is not investment advice.
Morgan Stanley downgrades Absci stock on TL1A setback and higher risk profile By Investing.com
Morgan Stanley downgraded Absci Corp. (NASDAQ:ABSI) from Overweight to Equalweight and lowered its price target to $4.32 from $5.80 due to increased risk and reduced visibility in near-term value creation. This follows Absci's disappointing Phase 1 data for its TL1A program ABS-101, leading the firm to pivot towards ABS-201 for androgenetic alopecia, a move Morgan Stanley sees as higher execution risk. The downgrade also considers Absci's evolving focus towards dermatology and cosmetology, areas where the firm has less underwriting comfort.
Absci (NASDAQ:ABSI) Shares Down 9.1% - Here's What Happened
Absci (NASDAQ:ABSI) shares dropped 9.1% on Thursday, closing at $3.655 after hitting an intraday low of $3.55, with trading volume 26% below average. The biotechnology company missed its recent quarterly earnings and revenue expectations significantly, reporting an EPS of -$0.20 against an estimate of -$0.19 and revenue of $0.38 million versus an estimated $1.58 million. Despite mixed but generally positive analyst ratings, the stock has experienced downgrades from some firms, and institutional investors have recently adjusted their positions.
Morgan Stanley downgrades Absci stock on TL1A setback and higher risk profile
Morgan Stanley has downgraded Absci Corp. to Equalweight from Overweight and reduced its price target to $4.32 due to increased risk and decreased visibility for near-term value creation. This follows disappointing Phase 1 data for its TL1A program ABS-101, leading Absci to explore alternative indications and partnering opportunities. The firm has now incorporated a new program, ABS-201 for androgenetic alopecia, into its model, but notes higher execution risk as Absci intends to develop and commercialize it independently.
Morgan Stanley Downgrades Absci Corp(ABSI.US) to Hold Rating, Cuts Target Price to $4.32
Morgan Stanley analyst Sean Laaman has downgraded Absci Corp (ABSI.US) from an unspecified previous rating to a 'Hold' rating. The target price for Absci Corp has also been reduced from $5.89 to $4.32. This decision is based on the analyst's past performance, which shows a 65.8% success rate and an average return of 10.6% over the last year, according to TipRanks data.
Morgan Stanley downgrades Absci stock on TL1A setback and higher risk profile
Morgan Stanley downgraded Absci Corp. (NASDAQ:ABSI) from Overweight to Equalweight and lowered its price target due to increased risk and reduced visibility after Absci's TL1A program showed disappointing Phase 1 data. Absci is now pivoting towards its ABS-201 program for androgenetic alopecia, which Morgan Stanley views as having higher execution risk. Despite this, Jones Trading raised its price target for Absci, maintaining a Buy rating.
Morgan Stanley downgrades Absci stock on TL1A setback and higher risk profile
Morgan Stanley downgraded Absci Corp. (NASDAQ:ABSI) from Overweight to Equalweight and significantly lowered its price target due to increased risk and reduced visibility after disappointing Phase 1 data for its TL1A program ABS-101. The company will discontinue internal development of ABS-101 and instead incorporate ABS-201, a program for androgenetic alopecia, into its model, which Morgan Stanley views as carrying higher execution risk due to its early stage and Absci's independent development plans.
Absci Corporation (ABSI) announces first participants dosed in phase 1/2a HEADLINE trial
Absci Corporation (ABSI) has announced that the first participants have been dosed in its phase 1/2a HEADLINE trial. This trial is a significant step forward for the biotechnology company as it progresses its drug development efforts. Further details on the trial's specifics and potential implications are anticipated to follow.
Absci unveils preclinical data for AI-designed ABS-201, targeting a novel hormonal pathway for hair loss treatment
Absci has released preclinical data for its AI-designed drug candidate, ABS-201, which aims to treat hair loss by targeting a previously unexplored hormonal pathway. This novel therapeutic approach could offer a new solution for androgenetic alopecia and other forms of hair loss, building on the company's AI drug discovery platform.
Absci Unveils Preclinical Data for AI-Designed ABS-201, Targeting a Novel Hormonal Pathway for Hair Loss Treatment
Absci Corporation (NASDAQ: ABSI) released preclinical data for ABS-201, an AI-designed antibody for androgenetic alopecia (AGA), demonstrating a novel approach to hair loss treatment. The data shows ABS-201 inhibits the PRLR signaling pathway, prolongs hair growth, and protects stem cell niches, suggesting it could reconvert vellus hairs into terminal follicles. This treatment targets hormonal signaling beyond androgens, potentially offering superior results compared to current treatments like minoxidil.
Absci Unveils Preclinical Data for AI-Designed ABS-201, Targeting a Novel Hormonal Pathway for Hair Loss Treatment
Absci Corporation (NASDAQ: ABSI) has released promising preclinical data for its AI-designed antibody, ABS-201, aimed at treating androgenetic alopecia (AGA) by targeting the prolactin receptor (PRLR). The study indicates that ABS-201 can inhibit the PRLR signaling pathway, prolong hair growth, and stimulate hair follicle stem cells, offering a potentially more effective treatment option than current standards like minoxidil. This novel approach addresses the root causes of follicle miniaturization beyond typical androgen pathways.
Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial
Absci Corporation (NASDAQ:ABSI) announced that the first healthy volunteers have been dosed in its Phase 1/2a HEADLINE clinical trial for ABS-201, an anti-prolactin receptor antibody developed using its generative AI system. This trial will evaluate the effectiveness, pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of ABS-201, with interim results expected in late 2026. H.C. Wainwright raised its price target for Absci to $8 from $7, maintaining a Buy rating, citing strong preclinical evidence for the ABS-201 program.
Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial
Absci Corporation announced that the first healthy volunteers have been dosed in its Phase 1/2a HEADLINE clinical trial for ABS-201, an anti-prolactin receptor antibody developed using its generative AI system. The trial will assess effectiveness, safety, and other pharmacological aspects, with interim results expected in late 2026. H.C. Wainwright increased its price target for Absci to $8 from $7, maintaining a Buy rating, based on the potential of ABS-201 for indications in women's health and dermatology, particularly its ability to impact hair follicle growth.
Morgan Stanley Assumes Coverage on Absci Corporation (ABSI) with $7 Target
Morgan Stanley has initiated coverage on Absci Corporation (ABSI) with an "Equal Weight" rating and set a price target of $7. This target suggests a potential upside of 45.4% from the stock's previous closing price.
Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential
Absci Corporation (NASDAQ: ABSI) has garnered a full buy consensus among analysts, with a median price target suggesting a 150.70% upside potential. H.C. Wainwright recently reaffirmed a 'Buy' rating and raised the price target to $8, citing the incorporation of ABS-201, an AI-designed antibody for androgenetic alopecia, into the company's model. Preclinical data indicates ABS-201's strong potential to stimulate hair growth and regenerate stem cells.
Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential
Absci Corporation (NASDAQ: ABSI) has garnered a full buy consensus from nine analysts, with a median price target of $9, suggesting a 150.70% upside potential. This optimism follows H.C. Wainwright reaffirming a ‘Buy’ rating and raising its price target on December 17, citing the firm's incorporation of ABS-201, an AI-designed antibody for androgenetic alopecia, into its model. Preclinical data for ABS-201, disclosed on December 11, indicates its potential to stimulate hair growth by targeting the prolactin receptor (PRLR)
Absci (NASDAQ:ABSI) Trading Up 11.1% - Time to Buy?
Absci (NASDAQ:ABSI) shares rose 11.1% on Monday, trading as high as $3.68 before closing at $3.7560, though volume was significantly below average. Analysts offer a "Moderate Buy" consensus with an average price target of $7.98, despite the company reporting weak fundamentals including missed earnings and revenue estimates, and negative margins. Institutional investors have been modifying their stakes in the biotechnology company.
HC Wainwright & Co. Maintains Absci (ABSI) Buy Recommendation
HC Wainwright & Co. has reiterated a Buy recommendation for Absci (ABSI) with a significant price target suggesting a 144.15% upside. The report highlights increased institutional ownership and a bullish put/call ratio, with key investors like ARK Investment Management increasing their stakes. Absci's projected annual revenue is expected to surge by 1,649.63% to $49MM.
ABSI Stock: HC Wainwright & Co. Raises Price Target to $8.00 | A
HC Wainwright & Co. has reiterated its Buy rating for Absci (ABSI) and increased the price target from $7.00 to $8.00, signaling confidence in the company's future performance. This updated target represents a 14.29% increase. Absci, an AI-powered synthetic biology company, receives an "Outperform" status from nine brokerage firms, with an average price target of $8.11, implying a significant upside from its current price.
Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside
Absci Corporation's ABS-201, an AI-designed antibody, has shown promising preclinical data for treating androgenetic alopecia by stimulating hair growth and preserving stem cells. Analysts from Needham and JonesTrading have reiterated Buy ratings, citing the drug's potential and strong market interest ahead of the planned HEADLINE study. The company's innovative approach targets a root cause of hair loss not addressed by current treatments, positioning ABS-201 for a significant market impact.
Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside
Absci Corporation's ABS-201, an AI-designed antibody, has shown promising preclinical data for treating androgenetic alopecia by stimulating hair growth and preserving stem cells. Analysts have reiterated Buy ratings, citing strong market interest and the drug's potential to offer a new approach to hair loss treatment. The company, a clinical-stage biopharmaceutical firm, is targeting a significant market of 80 million Americans affected by this condition.
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Raises Target Price to $8
H.C. Wainwright analyst Swayampakula Ramakanth has reiterated a Buy rating for Absci Corp (ABSI.US) and increased the target price from $7 to $8. According to TipRanks, the analyst has a 43.4% success rate and an 18.4% average return over the past year. This revised target suggests continued confidence in Absci Corp's financial outlook.
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Absci Corporation, a clinical-stage biopharmaceutical company utilizing generative AI, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Absci management is scheduled to present on January 14, 2026, where they will discuss their Integrated Drug Creation™ platform and their pipeline of AI-designed therapeutics, including ABS-201™ for hair regrowth and endometriosis. A live and archived webcast of the presentation will be available on the company’s investor relations website.
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company utilizing generative AI for drug discovery, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Absci management is scheduled to present on Wednesday, January 14th at 3:45 p.m. Pacific Time. The company is advancing its Integrated Drug Creation platform to design innovative therapeutics, including its pipeline candidate ABS-201 for hair regrowth and endometriosis.
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Absci Corporation announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where its management will present on January 14th at 3:45 p.m. Pacific Time. The company, a clinical-stage biopharmaceutical firm, will discuss its Integrated Drug Creation™ platform and showcase its AI-designed therapeutic pipeline, including ABS-201™ for hair regrowth and endometriosis treatment. A live webcast of the presentation will be available on their investor relations website.
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Absci Corporation, a clinical-stage biopharmaceutical company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The company's management is scheduled to present on January 14, 2026, where they will discuss their Integrated Drug Creation™ platform, which utilizes generative AI and a synthetic biology data engine for drug discovery. Absci is advancing its own pipeline of AI-designed therapeutics, including ABS-201™ for hair regrowth and endometriosis.
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
Absci Corporation, a clinical-stage biopharmaceutical company, has announced that the first participants have been dosed in its Phase 1/2a HEADLINE™ trial for ABS-201™, an AI-designed antibody targeting androgenetic alopecia (AGA). This trial will evaluate the safety, tolerability, and efficacy of ABS-201, which is designed to target the prolactin receptor, a key driver for hair loss and endometriosis. Interim data for AGA are expected in the second half of 2026, and the company also plans to initiate Phase 2 clinical development for endometriosis in late 2026, leveraging the data from the AGA study.
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7
Needham analyst Gil Blum has reiterated a Buy rating for Absci Corp (ABSI.US) and maintained a target price of $7. Blum has a 39.8% success rate and a 7.7% average return over the past year, according to TipRanks data. The information presented is for informational purposes only and not investment advice.
